Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for Dr Reddys Laboratories (RDY) over the last 8 years, with Mar 2025 value amounting to $172.0 million.

  • Dr Reddys Laboratories' Cash & Equivalents rose 102.35% to $172.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $172.0 million, marking a year-over-year increase of 102.35%. This contributed to the annual value of $172.0 million for FY2025, which is 102.35% up from last year.
  • Dr Reddys Laboratories' Cash & Equivalents amounted to $172.0 million in FY2025, which was up 102.35% from $85.0 million recorded in FY2024.
  • Dr Reddys Laboratories' Cash & Equivalents' 5-year high stood at $203.0 million during FY2021, with a 5-year trough of $70.0 million in FY2023.
  • Its 3-year average for Cash & Equivalents is $109.0 million, with a median of $85.0 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 651.85% in 2021, then tumbled by 64.29% in 2023.
  • Yearly analysis of 5 years shows Dr Reddys Laboratories' Cash & Equivalents stood at $203.0 million in 2021, then declined by 3.45% to $196.0 million in 2022, then plummeted by 64.29% to $70.0 million in 2023, then increased by 21.43% to $85.0 million in 2024, then spiked by 102.35% to $172.0 million in 2025.